Is chronic inflammation really behind heart disease, diabetes and cancer?

Acute inflammation is the immune system's rapid, targeted response to an injury or pathogen. Immune cells rush to the site, neutralize the threat, and then stand down. The whole process typically resolves within days. Chronic inflammation is fundamentally different: it involves a sustained, low-grade activation of the innate immune system that persists for months to years¹. Key markers include elevated C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α).

How Chronic Inflammation Drives Disease

Cardiovascular disease. Atherosclerosis is no longer viewed as a simple plumbing problem of cholesterol buildup. Inflammatory cells infiltrate arterial walls, destabilize plaques, and trigger the ruptures that cause heart attacks and strokes³. The landmark CANTOS trial demonstrated that reducing inflammation with a targeted antibody (canakinumab) lowered cardiovascular event rates independent of cholesterol levels.

Cancer. Chronic inflammation creates a microenvironment rich in reactive oxygen species and growth factors that promote DNA damage, tumor initiation, and metastasis². An estimated 15-20% of cancers are linked to chronic inflammatory conditions — for example, inflammatory bowel disease increases colorectal cancer risk.

Type 2 diabetes. Excess adipose tissue, especially visceral fat, secretes pro-inflammatory cytokines that interfere with insulin signaling. This inflammation-driven insulin resistance is now understood to be a central mechanism in the progression from metabolic syndrome to full-blown diabetes⁴.

Autoimmune conditions. In diseases like rheumatoid arthritis, lupus, and multiple sclerosis, the immune system's inflammatory machinery attacks the body's own tissues. While these conditions have genetic components, environmental triggers — including diet — modulate the severity of the inflammatory response.

Common Drivers

The major lifestyle factors that promote chronic inflammation include poor diet (high in refined sugar, processed foods, and trans fats), physical inactivity, chronic stress, poor sleep, smoking, and excess alcohol consumption¹.

Furman et al. (2019) published a comprehensive review in Nature Medicine establishing chronic systemic inflammation as a unifying mechanism across the major non-communicable diseases¹. The authors coined the term "inflammaging" to describe the age-related increase in baseline inflammatory markers and presented evidence that lifestyle interventions — particularly dietary changes — can meaningfully reduce these markers.

The connection between inflammation and cardiovascular disease has been studied for decades, but the field was transformed by the CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study). Raggi et al. (2018) reviewed the mechanistic evidence showing that inflammatory cells actively participate in every stage of atherosclerosis, from fatty streak formation to plaque rupture³. Importantly, individuals with elevated CRP but normal LDL cholesterol still carry significant cardiovascular risk, reinforcing that inflammation is an independent driver.

Greten and Grivennikov (2019) reviewed the origins of inflammation in tumors and the mechanisms by which inflammation drives tumor initiation, growth, progression, and metastasis². Their review in Immunity described how cancer cells and the surrounding stromal and inflammatory cells engage in reciprocal interactions to form an inflammatory tumor microenvironment, and how tumor-promoting inflammation closely resembles the inflammation seen during development, immunity, tissue homeostasis, and tissue repair.

Rohm et al. (2022) reviewed how obesity leads to chronic, systemic inflammation that can lead to insulin resistance, β-cell dysfunction, and ultimately type 2 diabetes⁴. Their review discussed how chronic tissue inflammation results in insulin resistance, impaired insulin secretion, and glucose intolerance, and how this inflammatory state contributes to long-term complications of diabetes, including non-alcoholic fatty liver disease, retinopathy, cardiovascular disease, and nephropathy. It also covered current therapeutic options for metabolic disease, including advances in the clinic and the potential of immune-modulatory approaches.

Taken together, these findings make a strong case that chronic inflammation is not just a symptom of disease — it is a driver. This understanding has shifted attention toward interventions that address inflammation at its root, with diet emerging as one of the most accessible and well-supported strategies.